News

Traditional pharmaceutical manufacturing has historically been associated with scale. Large batches are manufactured, tested and released for thousands or millions of patients. Precision medicine is helping to change that model. Some emerging therapies target increasingly defined patient populations. Others, particularly advanced therapies, may involve extremely small manufacturing campaigns or even patient-specific material. That shift

Efficiency and compliance are sometimes presented as competing priorities in pharmaceutical manufacturing. One side wants faster processes, less paperwork and lower costs. The other wants controls, documentation and assurance. That is an increasingly outdated way of looking at quality. A mature Pharmaceutical Quality System should be capable of improving efficiency while protecting patients and

Outsourcing has become an established part of modern pharmaceutical manufacturing. Drug developers may depend on Contract Manufacturing Organisations (CMOs), Contract Development and Manufacturing Organisations (CDMOs), testing laboratories, packaging specialists, logistics providers and raw-material suppliers spread across multiple countries. The advantages are significant. Outsourcing can provide specialist expertise, additional manufacturing capacity, access to advanced technologies

Electronic Quality Management Systems have become central to the way pharmaceutical organisations manage deviations, CAPAs, change controls, audits, training, documentation and other critical quality processes. Yet the more important an eQMS becomes to an organisation, the more complicated upgrading it can become. What may appear to be a straightforward software project can quickly become

Quality Assurance sits at the heart of pharmaceutical manufacturing. Every medicinal product that reaches a patient must be manufactured, tested, documented, stored and released according to strict quality and regulatory requirements. Behind those processes are Quality Assurance professionals helping to ensure systems remain compliant, risks are controlled and product quality is consistently maintained. One

Quality Assurance has always played a critical role within the pharmaceutical industry. Today, however, the demands placed on QA professionals are evolving rapidly. Pharmaceutical manufacturing is becoming more technologically advanced, regulatory expectations continue to develop, and Quality Systems are increasingly expected to support risk-based decision-making, digitalisation and continual improvement. For QA professionals considering their

The pharmaceutical industry has never been more global. Active pharmaceutical ingredients may be manufactured in one country, processed in another, packaged elsewhere and ultimately supplied to multiple markets. Yet while pharmaceutical supply chains continue to become more interconnected, the regulatory environments governing them do not always move at the same speed. International initiatives such

Facility expansions and new line start-ups are often seen as positive milestones for pharmaceutical companies. They may signal growth, increased capacity, new product introductions, improved technology or a stronger market position. However, from a Quality Assurance perspective, they also represent periods of heightened risk. When a new manufacturing area, packaging line, laboratory, warehouse space,

The pharmaceutical factory is changing. For decades, quality decisions were often made after the event: after a batch record was reviewed, after laboratory results were returned, after a deviation was raised, or after a trend was identified during periodic review. Today, the growth of connected manufacturing systems, automated process controls, electronic batch records, manufacturing

In pharmaceutical manufacturing, raw materials are often discussed as inputs. In reality, they are far more than that. They are one of the foundations of product quality, process consistency, regulatory compliance and patient safety. As global supply chains become more complex, and as pharmaceutical companies face greater pressure around resilience, cost, continuity of supply